JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma
Status:
Recruiting
Trial end date:
2023-11-17
Target enrollment:
Participant gender:
Summary
Small cell esophageal carcinoma (SCCE) is a kind of malignant tumor with poor prognosis. Our
study found that the mutation spectrum and somatic CNV spectrum of SCCE were similar to those
of esophageal squamous cell carcinoma (ESCC). Paclitaxel combined with cisplatin or
carboplatin is the first-line treatment for ESCC. JS001 is a Chinese anti-PD-1 monoclonal
antibody, which has been approved for the treatment of melanoma. This is a prospective,
single arm, single center, phase II clinical trial of JS001 combined with nab-paclitaxel and
cisplatin or carboplatin in the first-line treatment of unresectable or advanced SCCE. Aim to
evaluate the safety and efficacy of this regimen in patients with unresectable or advanced
SCCE.